Loading
Instead of finding a different target for each cancer, hit the scaffolding cells that almost all solid tumours share.
Rather than finding a different target for each cancer, this idea hits the cancer-associated fibroblasts that almost all solid tumours share. FAP-targeted alpha or beta radioligands such as FAP-2286 would be given to FAPI-PET-avid pancreatic, gastric and sarcoma patients irrespective of tumour-cell genotype, delivering radiation to the stroma with crossfire into adjacent tumour cells and depleting the fibroblasts that exclude T cells. Stroma is genetically stable, so resistance mutations are not expected. The test is phase 2 FAP-2286 cohorts selected by FAPI PET, with paired biopsies and a PD-1 combination in pancreatic cancer. At early-clinical maturity it addresses the bottleneck Cold tumours and the immunosuppressive microenvironment.
Shares FAP-2286 (177Lu / 68Ga), A university cyclotron network with shared regulatory files for new tracers, FAPI PET, FAP.
Shares FAP, Targeted alpha therapy, Radioligand therapy (beta emitters), Sarcomas (soft tissue, bone, GIST).
Shares FAP-2286 (177Lu / 68Ga), FAPI PET, Radioligand therapy (beta emitters).
Shares A university cyclotron network with shared regulatory files for new tracers, FAPI PET, FAP.
Shares FAPI PET, FAP, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma.
Shares Reprogramme the stroma rather than remove it: second-generation stromal trials with a stromal biomarker and a survival endpoint, FAPI PET, FAP, Radioligand therapy (beta emitters).
Shares FAP-2286 (177Lu / 68Ga), FAPI PET, FAP, Radioligand therapy (beta emitters).
Shares FAPI PET, FAP, Pancreatic ductal adenocarcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/